Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9826113 | 0.79 | ALDH1A1 (0.43) | LMNAKDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL9826271 | 0.77 | KDM4E (0.38) | LMNAKDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL9827215 | 0.76 | SMN1; SMN2 (0.41) | KDM4ESMN1; SMN2ALDH1A1HTTNPC1 | |
| SCHEMBL811232 | 0.76 | KMT2A (0.50) | LMNASMN1; SMN2ALDH1A1HTTMAPT | |
| SCHEMBL9827017 | 0.74 | ALDH1A1 (0.43) | LMNAKDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL11564103 | 0.74 | — | — | |
| SCHEMBL10570024 | 0.72 | MAOA (0.41) | KDM4EALDH1A1MAPTNPSR1MEN1 | |
| SCHEMBL8555731 | 0.72 | — | — | |
| SCHEMBL11583412 | 0.68 | — | — | |
| SCHEMBL6845036 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705294-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | Aurigene Oncology Limited (IN) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024228132-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS CCR4 MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-11-07 | — | — | WO | disclosed |
| EP-3372601-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2022-09-21 | — | — | EP | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-10793582-B2 | Bicyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3372601-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9434731-B2 | Imidazo-, pyrazolopyrazines and imidazotriazines and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| EP-0169813-B1 | PHOTOGRAPHIC RECORDING MATERIAL FOR THE SILVER DYE-BLEACHING PROCESS | CIBA-GEIGY AG (CH) | 1992-04-15 | — | — | EP | disclosed |
| EP-0301613-B1 | THIAZOLE COMPOUNDS HAVING FUNGICIDAL ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1991-07-10 | — | — | EP | disclosed |
| US-4889863-A | NONPHYTOTOXIC; SEEDS, SOILS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1989-12-26 | — | — | US | disclosed |
| EP-0301613-A1 | Thiazole compounds having fungicidal activity | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1989-02-01 | — | — | EP | disclosed |
| US-4743683-A | FOR DYE BLEACH PROCESS, PHOTOGRAPHY | CIBA-GEIGY AG (CH) | 1988-05-10 | — | — | US | disclosed |
| US-4661437-A | COLORFASTNESS | CIBA-GEIGY AG (CH) | 1987-04-28 | — | — | US | disclosed |
| EP-0169813-A2 | Photographic recording material for the silver dye-bleaching process | CIBA-GEIGY AG (CH) | 1986-01-29 | — | — | EP | disclosed |
| US-4153607-A | Process for the production of 4,5-disubstituted thiazoles | BASF AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233438-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | KAT2A, KAT7, KAT5 | LMNA 4276/4885KDM4E 418/4885SMN1; SMN2 4513/4885 |
| US-10793582-B2 | Bicyclic heterocyclic compound | KAT2A, KAT7, KAT5 | LMNA 4153/4885KDM4E 383/4885SMN1; SMN2 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.